Novocure wins reimbursement from Humana for Optune brain cancer device

NovoCure (NSDQ:NVCR) said today it won reimbursement from Humana for treatments with its Optune device for patients with recurrent glioblastoma. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” to inhibit cancer cell replication and cause cancer cell death. The new reimbursement win brings the number of commercial payers covering Optune treatment up to 9, NovoCure said in a press release. In January, NovoCure said  it applied for a supplemental pre-market approval from the FDA for the 2nd generation of its Optune device for treating glioblastoma, a form of brain cancer. The FDA approved Optune’s 1st iteration in April 2011. NovoCure said it pared the weight of the newer version, which hit the European market last October, from 6 pounds to 2.7 pounds using digital signal generation technology. Last December, NovoCure touted positive data from a pivotal Phase III trial of the Optune device in combination with standard-of-care temozolomide for treating newly diagnosed glioblastoma, which was halted early for success. The post Novocure wins reimbursement from Humana for Optune brain cancer device appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Oncology NovoCure Source Type: news

Related Links:

Authors: Shibata N, Matsumoto K, Kitamura S, Sakashita A, Kizawa Y, Hirata KI Abstract A 67-year-old woman was admitted to our hospital due to an acute onset of consciousness disturbance, aphasia and left hemiplegia. Computed tomography revealed multiple systemic infarctions, including brain, kidney and spleen. Transesophageal echocardiography revealed vegetations attached to the mitral valve leaflets, which was suspected to be the embolic source. Repeated blood cultures were negative, and advanced lung cancer was incidentally revealed by computed tomography. She was then diagnosed with nonbacterial thrombotic endo...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
This study also provides further functional and biochemical evidence of the mechanisms of CICI. Using novel object recognition (NOR), we demonstrated the Dox administration resulted in memory deficits, an effect that was rescued by MESNA. Using hydrogen magnetic resonance imaging spectroscopy (H1-MRS) techniques, we demonstrated that Dox administration led to a dramatic decrease in choline-containing compounds assessed by (Cho)/creatine ratios in the hippocampus in mice. To better elucidate a potential mechanism for this MRS observation, we tested the activities of the phospholipase enzymes known to act on phosphatidylchol...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conditions:   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer Intervention:   Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) Sponsor:   Northwell Health Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Brain Diseases;   Brain Cancer Interventions:   Device: Wiersma Head Stabilizer;   Device: AlignRT system Sponsor:   University of Chicago Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer Intervention:   Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) Sponsor:   Northwell Health Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Brain Diseases;   Brain Cancer Interventions:   Device: Wiersma Head Stabilizer;   Device: AlignRT system Sponsor:   University of Chicago Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In the next 5-7 years, the bioprinting market is estimated to expand by 15.7 percent, and it is anticipated to grow over $4.70 billion by 2025, according to the latest study of BIS Research. While the growth statistics indicate a turbulent landscape, it is worth familiarizing with the main players. Here, we collected the best bioprinting companies currently on the market. The future of bioprinting: tissues not organs The idea of lab-grown organs might mean the end of testing drugs on animals or humans, the solution for organ shortages and an ending of the desperate state of organ donations worldwide. If the creators of the...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: 3D Printing in Medicine Biotechnology Business Future of Medicine 3d printed bioprinting company Healthcare Innovation market regenerative skin Source Type: blogs
Melanoma is a type of cancer that affects the skin cells. If it has progressed to stage 4, this means it has spread beyond the skin to other organs, such as the liver, brain, or lungs. In this article, learn about survival rates, traditional treatments, and new treatment methods, such as targeted therapy drugs.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
(Georgetown University Medical Center) A valuable cache of brain cancer biomedical data, one of only two such large collections in the country, has been made freely available worldwide by researchers at Georgetown Lombardi Comprehensive Cancer Center.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Patients with glioblastoma, a persistent and difficult to treat brain cancer, often end up suffering through multiple rounds of chemo and radiation therapy. Scientists at MIT have been working on harnessing the power of artificial intelligence to bet...
Source: Medgadget - Category: Medical Devices Authors: Tags: Informatics Neurology Oncology Source Type: blogs
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Medical Devices | Neurology | Temodar